热门站点| 世界资料网 | 专利资料网 | 世界资料网论坛
收藏本站| 设为首页| 首页

Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-05-10 20:33:16  浏览:8153   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载
代物清偿,抑或债的更新?
——兼评原告石某诉被告张某买卖合同货款纠纷一案
张化平

[内容摘要]
债权人与债务人之间就债务偿还问题答成的新协议是代物清偿协议还是属于债的更新,在债务人不履行新协议时是按原协议起诉还是依据新协议起诉,这在法律实务中是常遇到的问题。本文就代物清偿的法律概念、构成要件及与债的更新之区别作了相应探讨。
[关键词]
债的履行 代物清偿 代物清偿协议 债的更新


[问题的提出]
2001年至2002年3月期间,原告石某向被告张某供应供应焦碳、生铁等原料。2003年3月15日经双方结算,被告向原告出具11575元欠条一张。原告经多次催要遭被告拒绝后,于2004年1月7日向法院提起诉讼,要求依法判令被告履行付款义务。原告起诉后的2月16日,被告主动与原告协商并达成协议一份,载明:“经双方友好协商,张某同意将规格1.5匹空调机3台、11KW鼓风机1台、生铁100KG和陶土3.5T抵扣欠石某材料款壹万壹仟伍佰柒拾伍元整,¥11575元,双方货款两清”。2月17日,原告石某向法院申请撤诉。3月初,原告雇请他人车辆往被告处要求其履行协议,在清点货物过程中,双方发生争执致原告拖货未果。2004年8月16日,原告以原欠条为依据,再次诉诸法院,要求判令被告给付11575元欠款。诉讼中,被告张某坚持仍以空调等物品抵款,原告石某则要求以货币履行(物品已贬值)。
[主要观点]
本案在法院审理过程中主要有两种观点:一种观点认为,双方当事人之间继欠条之后又达成一份以货抵款协议,致使双方之间的法律关系性质发生变化,从原来的基于欠条的债权债务法律关系转化为以货抵款协议的新的合同法律关系。原告石某以原欠条起诉,其请求不能成立;原告应以后一协议向对方追偿合同之债。
另一种观点认为,原、被告达成的是一份代物清偿协议,代物清偿协议成立时,原债务并不消灭。代物清偿协议生效履行的关键在于有受领权的人现实地受领给付物。未发生现实受领给付的代物清偿协议,不能发生约定的效力和法律后果。故原告有权以原欠条为依据,提起给付之诉,以求自身权益的充分保护。
[作者的观点]
笔者认为,处理本案的关键在于对2月16日协议性质的正确认识,该协议是代物清偿还是属于债的更新。在现实经济生活中,债权人与债务人协商以物品或劳务抵还金钱债务较为常见,最典型的如上例之情形。由于我国法律未规定债的代物清偿制度,法学理论著作亦鲜有论及,司法实践中对债的代物清偿之要件、效力等基本内容缺乏正确的把握,常把代物清偿认定为债的更新,导致对同类案件的处理大相径庭,从而有损法律适用的安定性和人民法院司法权威性。本文拟对相关问题作一简要探讨,以期抛砖引玉。
一、代物清偿的涵义与特征
(一)、代物清偿的涵义
代物清偿,亦称债的代物给付,为清偿债务的方法之一,是指以他种给付代替原定给付的清偿,也即债权人同意债务人以负担新的债务作为履行原来债务的方法,在新债务未履行前,原债务并不消灭,当新债务履行后,原债务同时消灭。
(二)、代物清偿的特征
1、代物清偿为合同
代物清偿是债务人为清偿原债务而对债权人负担新债务,仍以当事人双方之意思表示一致为基础,故性质上为仍为合同。代物清偿合同通常由债权人与债务人订立,但是既然法律允许第三人清偿债务,代物清偿合同亦不妨由第三人与债权人订立。 代物清偿虽为合同,但并非当事人双方变更(更改)了前合同的内容,它只是履行方法(或标的)的变更,比如前合同履行标的是货币,后合同以房产代替,又如以劳务代替。代物清偿既为合同,则其签订、履行自应受合同法的规范,如:当事人必须有行为能力,意思表示必须真实,内容必须合法,等等。
2、代物清偿成立时原债务并不消灭
代物清偿合同成立时,债务人即负有履行新债务之义务,但对债权人而言,其原债权并未因代物给付合同的成立而归于消灭,债务人负担新债务乃是作为履行原债务的一种方式,新债务与原债务基于同一目的同时并存,只不过在履行期内债权人只能就新债务请求履行,新债务获满足后,原债务同步消灭。当然,根据合同自由原则,当事人亦不妨约定,代物清偿合同成立时,原债务即归于消灭,此种约定亦为有效,但此时即成立债法上的另一制度——债的更新,非属代物清偿。
二、代物清偿的构成要件
(一)必须有原债务存在
代物清偿系以清偿原债务为目的而负担新债务。因而代物清偿是有因行为,故应有原债务存在,代物清偿合同才能有效成立。倘若原债务不存在或无效或被撤销时,则为代物清偿合同之成立原因不存在或不合法,新债务自然不能成立。此种情况下,如果债务人已履行了新债务,可依不当得利之规定,请求债权人予以返还。
(二)必须以他种给付代替原定给付
代物清偿的“物”即履行的标的或在种类上或在性质上须不同于原定给付的标的。债的履行标的有财产、劳务与权利三种,原定以财产交付,现以劳务代替,此乃履行标的性质不同,原定以房屋交付,现以汽车交付,此乃履行标的种类不同。代物清偿只是履行标的或方式的改变。允许债务人以他种给付替代原定给付,是对债务人履行不能作出救济,这也并不损害债权人的任何利益。原定给付与替代给付在价值上一般需要相等,但如果在双方同意的情况下,也允许有部分差额。
(三)、必须有当事人双方关于代物清偿的合意
代物清偿既为合同行为,故须债权人与债务人之间有负担新债务以清偿旧债务之意思表示,要经过当事人双方要约和承诺。代物清偿协议是双方合意的产物,该协议自双方达成合意时成立。当然,债务既然可以由第三人清偿,自然也可以由第三人与债权人订立代物清偿合同 。如第三人与债权人订立合同,自愿承担原债务人的债务,但其新债务与原债务的主要内容相同时,则仅成立债务的转移,只有第三人承担的新债务与原债务履行标的相异时,才成立代物清偿。
(四)必须有债权人等有受领权的人现实地受领给付
仅有双方当事人答成合意,代物清偿协议成立,但并不生效,不产生合同上的权利义务关系,如同借用合同、保管合同一样,代物清偿协议在合同理论上属于实践性合同,必须有当事人一方实际交付标的物的行为,才能产生法律上的效果。
三、代物清偿的效力
(一)、代物清偿合同成立后,新债务当然成立。但此新债务并非原债务的继续,而是异于原债务之另一个债务。因此,关于原债务之抗辩,在新债务不得主张,此点应该是债权人接受代物清偿主要的利益所在,因为债务人不得以关于原债务的抗辩对抗债权人,债权人在代物清偿更容易实现债权。
(二)代物清偿合同成立后,新债务之清偿期未届至之前,债权人不得行使原债权。只有新债务不能履行,或无效或被撤销时,始能就原债务请求履行。因为虽然债权人有两个债权,但债权人既已同意债务人以新债务清偿原债务,即对债务人负有一定义务,也就是说,应先自新的、独立的债权寻求满足,债务人如履行了新债务,则等于同时履行了原债务。
(三)代物清偿合同成立后,如果新债务没有履行,原债务就并不消灭,所以原债务之担保等从债务自亦继续存在。这是因为当事人签订代物清偿合同,系以清偿原债务为目的,换个角度说,即是债务人对原债务的确认,因而,如代物清偿合同系债权人与债务人签订,则原债务之诉讼时效即应中断、重新起算,合同如仅系第三人与债权人订立,则原债务之诉讼时效不中断。
(四)新债务与原债务如均已届清偿期,则因新债务不履行时,其原债务并不消灭,债权人自然可以请求履行新债务,亦可以请求履行原债务。债务人如履行新债务时,原债务随同消灭;反之,如债务人履行原债务时,新债务失去了存在的原因亦随同消灭。
(五)如代物清偿合同系由第三人与债权人订立,则债权人是行使原债权还是行使新债权,不受限制。
四、代物清偿与债的更新之区别
(一)、债的更新的涵义
所谓债的更新(也称债的更改),是指设定新债以代替原债务并使原债务归于消灭的民事法律行为,也即当事人双方基于某种原因答成新的协议以完全代替原协议,新协议是以消灭原债为目的而设立的 ,新协议成立后,原债归于消灭。如当事人双方以买卖合同法律关系代替原来的租赁合同法律关系。债的更新起源于罗马法,后法国民法典及日本民法典从之。
(二)、债的更新的构成要件
债的更新构成要件如下:(1)须已经存在一个债务;(2)须产生一个新债务;(3)新债务的产生须以原债务为基础,但其要素、内容相异;(4)当事人须有更新债务的意思表示。
(三)、代物清偿与债的更新的区别
代物清偿与债的更新均系为债的清偿方法, 均系由债务人承担新的债务以履行原债务,二者之间极为相似,区别细微,在实务当中更是难以区分。
笔者认为,应从以下几个方面把握二者之间的区别:
1、依债的更新,债权人以新取得的债权代替原债权,依代物清偿,债权人只是受领他种现实给付而代替原定给付;
2、债的更新中原债消灭后有新债产生,代物清偿则不会产生新债;

关于开展现有钢铁生产企业环境保护核查的通知

环境保护部


关于开展现有钢铁生产企业环境保护核查的通知

环办[2010]128号


各省、自治区、直辖市环境保护厅(局),新疆生产建设兵团环境保护局:

  为贯彻落实《国务院办公厅关于进一步加大节能减排力度 加快钢铁工业结构调整的若干意见》(国办发〔2010〕34号)要求,提高现有钢铁生产企业污染防治水平,我部决定开展现有钢铁生产企业环境保护核查。现将《现有钢铁生产企业环境保护核查办法(试行)》(以下简称《办法》)印发给你们,请遵照执行。

  我部将依照《办法》定期分批对现有钢铁生产企业开展核查。各省级环保部门应于2010年10月15日前将辖区内第一批钢铁生产企业预核查结果及相关材料(附光盘)报送环境保护部。我部将于2010年11月底前审查发布第一批环境保护核查合格钢铁生产企业名单。

  联系人:环境保护部污染防治司 王晓密      

  电话: (010)66556277,(010)66556244(传真)

  信箱: wang.xiaomi@mep.gov.cn

  附件:现有钢铁生产企业环境保护核查办法(试行)

  二○一○年九月二十日

主题词:环保 钢铁 核查 通知

抄送:工业和信息化部、发展改革委、国资委,华北、华东、华南、西北、西南、东北环境保护督查中心,中国钢铁工业协会,中国五矿化工进出口商会,各有关钢铁企业。

附件:

现有钢铁生产企业环境保护核查办法(试行)

  为贯彻落实《国务院办公厅关于进一步加大节能减排力度加快钢铁工业结构调整的若干意见》(国办发〔2010〕34号)要求,提高现有钢铁生产企业污染防治水平,指导现有钢铁生产企业环境保护核查工作,特制定本办法。

  一、适用范围

  本办法适用于中华人民共和国境内(港澳台地区除外)的现有钢铁联合、冶炼企业(以下简称“现有钢铁生产企业”)。

  现有钢铁生产企业,可以向所在地省级环保行政主管部门申请环境保护核查。

  二、申请及核查程序

  钢铁生产企业向所在地省级环保行政主管部门提出环境保护预核查的申请,并提交相关证明材料。省级环保行政主管部门对申请单位提交的证明材料进行核查,并进行现场检查。

  对辖区内预核查符合条件的现有钢铁生产企业,省级环保行政主管部门统一出具环境保护预核查钢铁生产企业推荐表(附一),附现有钢铁企业生产及环保设施基本情况表(附二),一并报告环境保护部。

  环境保护部组织专家对申请材料进行核查,并将核查结果在环境保护部网站公示5个工作日,对经公示无异议的,列入环境保护核查合格钢铁生产企业名单并予发布。

  三、核查时间和频次

  环境保护部每年组织两次现有钢铁生产企业环境保护核查。各省、自治区、直辖市环保部门应依企业申请定期对辖区内的现有钢铁生产企业进行核查,并于每年4月15日和10月15日前将核查结果报送环境保护部。

  四、环境保护核查内容和核查规则

  钢铁生产企业应当同时满足下列八项条件,省级环保行政主管部门方可出具预核查合格证明。

  (一)依法执行了建设项目(包括新、改、扩建项目)环评审批和竣工验收制度

  1.环境影响报告(书/表)取得相应级别的环保行政主管部门批复;

  2.建设项目竣工后,取得相应级别环保行政主管部门的竣工环保验收批复;

  3.未依法履行建设项目环境影响评价审批的钢铁生产企业需要补办环境影响评价审批,办理竣工环境保护验收手续,并取得相应级别的环保行政主管部门批复。

  (二)达标排放

  1.过去一年废水、废气、厂界噪声等各项污染物排放达到国家或地方污染物排放标准要求。附近居民无关于噪声或无组织排放等环境问题的投诉,或投诉问题已得到解决。

  2.排放执行行业标准的,按照行业标准进行全指标监测;执行综合排放标准的,按照环境影响报告书和地方环保部门指定的指标监测。

  3.废水、废气每季度至少监测一次。初次申请核查的现有钢铁生产企业,还应提供三个月以内由省级或地市级环境监测站出具的监测报告。

  (三)危险废物、一般工业固体废物以环境无害化方式利用或处置

  1.钢铁生产企业产生的含锌废物、含铬废物、废酸、废油和焦化产生的焦油渣、再生器残渣、生化污泥等属于危险废物的,应依法进行无害化处置。需要转移的,应按《危险废物转移联单管理办法》有关规定执行。

  2.自行处置或利用危险废物的,其专用设施需根据《固体废物污染环境防治法》(以下简称《固体法》)第十四条的规定,进行环境影响评价。委托他人代为处置的,须提供处置单位资质证书。

  3.钢铁工业污水处理产生的污泥须根据《危险废物鉴别标准 浸出毒性鉴别》(GB 5085.3)进行鉴别。属于危险废物的,应按第1款要求进行处置或利用。

  4.一般工业固体废物自行处置或综合利用的,应当提供最终排放去向说明或与综合利用单位的合同。

  (四)污染物排放达到总量控制要求

  1.企业排污量符合所在地环保行政主管部门分配给该企业的总量控制指标要求。

  2.完成主要污染物总量减排任务。

  (五)按期足额缴纳排污费

  (六)主要污染物产排污强度符合以下要求:

  吨钢污水排放量不超过2.0m3,吨钢烟粉尘排放量不超过1.0kg,吨钢二氧化硫排放量不超过1.8kg。

  (七)近三年未发生重大环境污染事故或重大生态破坏事件

  遵守国家和地方相关法律、法规和政策,近三年未发生重大及以上环境污染事故或重大生态破坏事件。

  (八)实施清洁生产审核并通过评估验收

  1.实施了清洁生产审核,向当地环保部门提交了清洁生产审核报告,并通过了清洁生产评估验收;

  2.根据《关于深入推进重点企业清洁生产的通知》(环发〔2010〕54号)中规定,每三年滚动实施一轮清洁生产审核。

  五、监督管理

  对于未通过环境保护部环境保护核查的钢铁生产企业,地方各级环保行政主管部门和环境保护部各督查中心应加强对其监督检查力度。

  环境保护部定期对通过环境保护核查的钢铁生产企业进行复查,发现有不符合本核查办法的,将取消其环境保护核查合格资格并予发布。

  附一:环境保护预核查钢铁生产企业推荐表
http://www.zhb.gov.cn/gkml/hbb/bgt/201009/W020100921516949105336.doc
  附二:现有钢铁企业生产及环保设施基本情况表
http://www.zhb.gov.cn/gkml/hbb/bgt/201009/W020100921516949118966.doc



版权声明:所有资料均为作者提供或网友推荐收集整理而来,仅供爱好者学习和研究使用,版权归原作者所有。
如本站内容有侵犯您的合法权益,请和我们取得联系,我们将立即改正或删除。
京ICP备14017250号-1